Rewrites headline, adds details and background in paragraphs 2-6, stock movement in paragraph 3
April 1 (Reuters) - U.S. medical device maker Becton Dickinson BDX.N is in talks with Thermo Fisher TMO.N and Danaher DHR.N for a potential sale of its life sciences unit, the Financial Times reported on Tuesday.
Becton Dickinson had in February announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, after the Financial Times reported that activist Starboard Value had taken a stake in the company and was pushing for the divestiture.
Its shares have fallen about 7.5% since then.
The unit could be worth as much as $21.5 billion, the FT reported, citing analysts at Bank of America.
Becton Dickinson is also exploring a so-called Reverse Morris trust tax-free deal with smaller diagnostics players such as Waters Corp WAT.N, Qiagen QIA.DE and Revvity RVTY.N, the report said, citing sources familiar with the matter.
Becton's biosciences and diagnostic solutions unit makes diagnostic products such as those used to detect infectious diseases and cancers.
Becton Dickinson, Thermo Fisher Scientific, Danaher, Waters Corp, Qiagen and Revvity did not immediately respond to a Reuters request for comment.
(Reporting by Surbhi Misra and Shubham Kalia in Bengaluru; Editing by Varun H K)
((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.